Skye Bioscience Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated CB1 Inhibitor, Nimacimab, in Patients With Obesity
Skye Bioscience推出CBeyond階段2臨床試驗,使用其差異化的CB1抑制劑Nimacimab,針對肥胖患者。
Skye Bioscience Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated CB1 Inhibitor, Nimacimab, in Patients With Obesity
Skye Bioscience推出CBeyond階段2臨床試驗,使用其差異化的CB1抑制劑Nimacimab,針對肥胖患者。
譯文內容由第三人軟體翻譯。